Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 7/20 | 0.59 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.59 |
| ▸ | MIF | P14174 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31474568 | 0.98 | P4HTM (0.57) | P4HTMP4HA1MIFKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL1828697 | 0.98 | P4HTM (0.57) | P4HTMP4HA1MIFKDM4EALDH1A1 | |
| SCHEMBL4558391 | 0.87 | MAP4K4 (0.55) | P4HTMP4HA1MIFKDM4EALDH1A1 | |
| SCHEMBL10815017 | 0.84 | MAOB (0.55) | P4HTMMAOBL3MBTL1 | |
| SCHEMBL4725410 | 0.84 | MAP4K4 (0.68) | P4HTMP4HA1MIFKDM4EALDH1A1 | |
| SCHEMBL1441384 | 0.82 | MAOB (0.53) | P4HTMMAOBL3MBTL1 | |
| SCHEMBL447835 | 0.80 | MAOB (0.56) | MAOBMAP4K4L3MBTL1 | |
| SCHEMBL1788326 | 0.80 | PTK2 (0.53) | P4HTMALDH1A1MAOBL3MBTL1 | |
| SCHEMBL8077534 | 0.80 | MAOB (0.51) | P4HTMMAOBL3MBTL1 | |
| SCHEMBL25414344 | 0.79 | MAOB (0.56) | P4HTMKDM4EALDH1A1MAOBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1358 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4008718-B1 | HETEROARYLAMIDOPYRIDINOL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF AUTOIMMUNE DISEASE | INNOVO THERAPEUTICS INC (KR) | 2024-10-30 | — | — | EP | claimed |
| CN-118239886-A | Morabamine compound and preparation method and application thereof | 重庆师范大学 | 2024-06-25 | — | — | CN | claimed |
| US-11697636-B2 | Substituted benzamides | HOFFMANN-LA ROCHE INC. (US) | 2023-07-11 | — | — | US | claimed |
| CN-109422675-B | Synthesis method of novel monoamine oxidase inhibitor molabemide | 重庆师范大学 | 2022-03-08 | — | — | CN | claimed |
| US-20210061760-A1 | SUBSTITUTED BENZAMIDES | HOFFMANN LA ROCHE (US) | 2021-03-04 | — | — | US | claimed |
| US-20200048194-A1 | SUBSTITUTED BENZAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2020-02-13 | — | — | US | claimed |
| EP-2855469-B1 | 5-AMINO[1,4]THIAZINES AS BACE 1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-06-19 | — | — | EP | claimed |
| EP-3083644-B1 | 5-ARYL-1-IMINO-1-OXO-[1,2,4]THIADIAZINES | HOFFMANN LA ROCHE (CH) | 2019-03-13 | — | — | EP | claimed |
| CN-109422675-A | A kind of New Style Monamine Oxidase Inhibition draws the synthetic method of shellfish amine | 重庆师范大学 | 2019-03-05 | — | — | CN | claimed |
| CN-108658852-A | New compound malabemide, preparation method and application thereof | 重庆师范大学 | 2018-10-16 | — | — | CN | claimed |
| EP-0385210-B1 | Amidation of pyridines | HOFFMANN LA ROCHE (CH) | 1995-02-15 | — | — | EP | claimed |
| US-5380861-A | Process for preparing pyridine 2-carboxamides | HOFFMANN-LA ROCHE INC. (US) | 1995-01-10 | — | — | US | claimed |
| EP-0573581-A4 | COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN | ARC 1 INC (US) | 1994-06-29 | — | — | EP | claimed |
| EP-0484437-A4 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | SEARLE & CO (US) | 1994-06-01 | — | — | EP | claimed |
| EP-0573581-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN | ARC 1, Inc. (US) | 1993-12-15 | — | — | EP | claimed |
| WO-1992014453-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN | ARC 1, INC. (US) | 1992-09-03 | — | — | WO | claimed |
| EP-0484437-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. Searle & Co. (US) | 1992-05-13 | — | — | EP | claimed |
| WO-1992001667-A1 | RENAL-SELECTIVE PRODRUGS FOR CONTROL OF RENAL SYMPATHETIC NERVE ACTIVITY IN THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1992-02-06 | — | — | WO | claimed |
| WO-1991001724-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1991-02-21 | — | — | WO | claimed |
| EP-0385210-A2 | Amidation of pyridines | F. HOFFMANN-LA ROCHE AG (CH) | 1990-09-05 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061760-A1 | SUBSTITUTED BENZAMIDES | TAAR1, TAAR5, NPY1R | P4HTM 1684/4885P4HA1 993/4885MIF 4035/4885 |
| US-20200048194-A1 | SUBSTITUTED BENZAMIDES | TAAR1, TAAR5, NPY1R | P4HTM 1684/4885P4HA1 993/4885MIF 4035/4885 |
| US-11697636-B2 | Substituted benzamides | TAAR1, TAAR5, NPY1R | P4HTM 1684/4885P4HA1 993/4885MIF 4035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.